Zacks Research Reduces Earnings Estimates for AngioDynamics

AngioDynamics, Inc. (NASDAQ:ANGO) – Equities research analysts at Zacks Research lowered their Q3 2026 earnings estimates for shares of AngioDynamics in a report issued on Tuesday, January 27th. Zacks Research analyst Team now anticipates that the medical instruments supplier will post earnings per share of ($0.10) for the quarter, down from their prior estimate of ($0.08). Zacks Research currently has a “Strong-Buy” rating on the stock. The consensus estimate for AngioDynamics’ current full-year earnings is ($0.37) per share. Zacks Research also issued estimates for AngioDynamics’ Q4 2026 earnings at ($0.07) EPS, Q1 2027 earnings at ($0.08) EPS, Q2 2027 earnings at ($0.05) EPS, Q3 2027 earnings at $0.03 EPS, Q4 2027 earnings at ($0.04) EPS, FY2027 earnings at ($0.13) EPS, Q1 2028 earnings at ($0.03) EPS and Q2 2028 earnings at ($0.02) EPS.

A number of other research analysts have also recently weighed in on the stock. Canaccord Genuity Group lifted their price objective on shares of AngioDynamics from $17.00 to $18.00 and gave the company a “buy” rating in a report on Friday, October 3rd. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of AngioDynamics in a research report on Wednesday, January 21st. Finally, Wall Street Zen downgraded shares of AngioDynamics from a “buy” rating to a “hold” rating in a research note on Sunday, December 21st. One analyst has rated the stock with a Strong Buy rating, three have given a Buy rating and one has given a Sell rating to the company. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $19.33.

AngioDynamics Trading Down 2.2%

ANGO opened at $10.01 on Thursday. The stock’s 50-day moving average price is $12.12 and its 200 day moving average price is $11.08. AngioDynamics has a 12-month low of $8.27 and a 12-month high of $13.99. The firm has a market cap of $412.61 million, a price-to-earnings ratio of -14.94 and a beta of 0.47.

AngioDynamics (NASDAQ:ANGO) last released its quarterly earnings results on Tuesday, January 6th. The medical instruments supplier reported ($0.15) EPS for the quarter, missing the consensus estimate of ($0.10) by ($0.05). AngioDynamics had a negative return on equity of 2.28% and a negative net margin of 9.02%.The firm had revenue of $79.43 million for the quarter, compared to analysts’ expectations of $76.43 million. During the same quarter in the prior year, the business earned ($0.04) earnings per share. The company’s quarterly revenue was up 9.1% on a year-over-year basis. AngioDynamics has set its FY 2026 guidance at -0.330–0.230 EPS.

Institutional Trading of AngioDynamics

Several institutional investors and hedge funds have recently bought and sold shares of the business. State of Alaska Department of Revenue purchased a new stake in shares of AngioDynamics in the third quarter valued at about $25,000. Farther Finance Advisors LLC lifted its holdings in shares of AngioDynamics by 146.4% during the fourth quarter. Farther Finance Advisors LLC now owns 2,018 shares of the medical instruments supplier’s stock worth $26,000 after purchasing an additional 1,199 shares during the period. Washington Trust Advisors Inc. purchased a new position in AngioDynamics in the 3rd quarter valued at $27,000. State of Wyoming purchased a new position in AngioDynamics in the 2nd quarter valued at $31,000. Finally, Russell Investments Group Ltd. increased its stake in AngioDynamics by 329.5% in the 3rd quarter. Russell Investments Group Ltd. now owns 4,188 shares of the medical instruments supplier’s stock valued at $47,000 after buying an additional 3,213 shares during the period. Hedge funds and other institutional investors own 89.43% of the company’s stock.

Trending Headlines about AngioDynamics

Here are the key news stories impacting AngioDynamics this week:

• Positive Sentiment: Zacks lifted its FY2027 EPS forecast to ($0.13) from ($0.18), a material improvement to the full‑year outlook that could support the stock as it signals recovering profitability versus prior expectations. MarketBeat
• Positive Sentiment: Zacks raised the Q1 2028 estimate to ($0.03) from ($0.06), narrowing the near‑term loss projection and easing immediate earnings pressure. MarketBeat
• Positive Sentiment: Zacks improved Q1 2027 to ($0.08) from ($0.10) and boosted Q3 2027 to $0.03 from ($0.03), the latter implying a return to quarter‑by‑quarter profitability — a bullish sign if sustained. MarketBeat
• Neutral Sentiment: Zacks kept a “Strong‑Buy” rating on ANGO, which affirms analyst conviction but may be priced in already. MarketBeat
• Neutral Sentiment: Zacks published a Q4 2027 EPS estimate of ($0.04) (no headline change reported) — a baseline item with limited immediate impact. MarketBeat
• Neutral Sentiment: Recent short‑interest entries reported zero shares / NaN changes — data appears invalid or not meaningful and should not be treated as a catalyst. MarketBeat
• Negative Sentiment: Zacks trimmed Q3 2026 to ($0.10) from ($0.08) and Q4 2026 to ($0.07) from $0.02 — notable downward revisions for the nearer‑term quarters that increase short‑term downside risk if results follow. MarketBeat
• Negative Sentiment: Zacks reduced Q2 2027 to ($0.05) from ($0.04) and cut Q2 2028 to ($0.02) from ($0.01), signaling some lingering near‑term weakness. MarketBeat

AngioDynamics Company Profile

AngioDynamics, Inc is a medical technology company headquartered in Latham, New York, that develops, manufactures and markets a broad range of minimally invasive medical devices. The company’s products focus on three core areas: vascular access, peripheral vascular intervention and interventional oncology. Its solutions are designed to improve procedural outcomes, reduce complications and enhance patient comfort in hospital and outpatient settings.

In the vascular access segment, AngioDynamics offers a portfolio of devices including implanted ports, peripherally inserted central catheters (PICCs), hemodialysis catheters and specialty blood management products.